In short
LTG-321 is an investigational medicine being studied for pain associated with osteoarthritis of the knee. One Phase 2 clinical trial is currently authorised in the European Union, planning to enrol 240 participants. The trial compares LTG-321 tablets against a matched placebo to see whether the substance reduces knee pain.
LTG-321 is an investigational substance being studied for pain associated with osteoarthritis of the knee. One Phase 2 clinical trial is currently authorised in the European Union, planning to enrol 240 participants. The trial compares LTG-321 tablets against a matched placebo to see whether the substance reduces knee pain.
Key points
- LTG-321 is an investigational substance with no marketing authorisation in these records
- The single authorised trial is a Phase 2 study in osteoarthritis of the knee
- The trial plans to enrol 240 participants
- The main measurement is the change in the WOMAC pain subscale score over each treatment period
- LTG-321 is given as a 270 mg oral tablet in the trial
- The trial status is Authorised, meaning it has not yet started recruiting
What is LTG-321?
LTG-321 is an investigational medicine that is being developed for the treatment of pain associated with osteoarthritis of the knee. The registry records do not list a marketing authorisation for this substance, which means it is not yet approved as a medicine for patients outside of clinical research. No trade names or other names for LTG-321 are given in the available data.
How does LTG-321 work?
The available registry data do not describe the mechanism of action of LTG-321. No information is provided about the molecular target of the substance or what blocking or activating that target does in the body. The trial record focuses on measuring whether LTG-321 reduces pain in people with osteoarthritis of the knee, but does not explain how the substance might achieve this effect.
Which conditions is LTG-321 being studied for?
- Osteoarthritis of the knee — a condition in which the cartilage in the knee joint wears down over time, causing pain, stiffness and reduced movement. The authorised trial is testing whether LTG-321 can reduce the pain associated with this condition.
How is LTG-321 given?
In the authorised trial, LTG-321 is given as a tablet taken by mouth. The trial lists two LTG-321 tablet formulations: one described as a 270 mg tablet and one described as a 270 mg/g tablet, both taken orally. The trial also includes a matched placebo for comparison.
What do the clinical trials show?
There is one clinical trial of LTG-321 in the registry records. It is a Phase 2 study in osteoarthritis of the knee, with a planned enrolment of 240 participants. The trial is currently in the status "Authorised", which means it has received regulatory approval to proceed but has not yet started recruiting participants. No results from this trial are available yet.
Who can take part in the LTG-321 trial?
The trial record does not list detailed eligibility criteria such as age limits or specific health requirements. The study is designed for people with osteoarthritis of the knee, as this is the condition being investigated. Anyone interested in taking part would need to be assessed against the full eligibility criteria, which are available in the trial record.
What is the main measurement in the trial?
The main measurement in the authorised trial is the change in the WOMAC pain subscale score. WOMAC stands for the Western Ontario and McMaster Universities Osteoarthritis Index, a questionnaire used to measure pain, stiffness and physical function in people with osteoarthritis of the knee or hip. The trial measures the change in the pain subscale score from before dosing at the start of each treatment period (Day 1 and Day 28) to the end of each treatment period (Day 14 and Day 41).
What side effects are known?
The available registry data do not list any side effects for LTG-321. Because the trial has not yet started, no safety information from this study is available. Side effect information is typically collected during clinical trials and reported once the study is completed or as results become available.